key: cord-0921962-irmhv8ef
authors: Calderon-Margalit, Ronit; Strahilevitz, Jacob; Paltiel, Ora
title: Commentary: Questioning the justification for a fourth SARS-CoV-2 vaccine
date: 2022-03-23
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.03.023
sha: b9024ca299759272d9f397ed021d46a2ae27fe1a
doc_id: 921962
cord_uid: irmhv8ef

nan

Considerable uncertainty exists worldwide as to the appropriate vaccination strategy in the face of repeated waves of SARS-CoV-2 caused by new variants. As of December 31, 2021, 65% of Israel's population aged >5 years had been fully vaccinated (defined as <6 months since 2 nd dose or recovery from COVID-19, or having received a 3 rd dose) against SARS-CoV-2. Of the 1.5 million Israelis aged 60+ years, 1.3 million (86.8%) were fully vaccinated, 94,008 (6.2%) were partially vaccinated, and 104,712 (7.0%) were un-vaccinated.

Israel was the first country to authorize a third, boosting, dose of the BNT162b2 vaccine in July 2021, when faced with a resurgence of COVID-19 caused mainly by the delta variant. This campaign was successful, resulting in estimated decreases of 91.1% and 94.8% for confirmed and severe cases, respectively (1) . Since the booster campaign, daily rates of severe COVID-19 have remained highest among the unvaccinated and lowest among the fully vaccinated who received the booster dose, with ratios of over 10:1 in the group over 60 years of age.

Starting in early December 2021, there was a gradual increase in confirmed COVID-19 cases in Israel with an unprecedented steep rise in January 2022, associated with social disruptions, hospital admissions and a shortage of healthcare personnel, similar to that observed in other countries afflicted by the SARS-CoV-2 omicron variant of concern.

In anticipation of the omicron surge, on December 21, 2021 Israel's Outbreak Control Team recommended a fourth dose for all healthcare workers, individuals with immunodeficiencies and all adults aged 60+ years. The major argument for this decision was that the expected benefit of reduced transmission and disease from a booster dose would outweigh potential risks. This recommendation was adopted by Attendant costs and potential harms of re-boosting have not been addressed.

Given the uncertainty regarding both protection and harms associated with a fourth dose, we conducted a simple assessment of the numbers needed to treat (NNT) to prevent one severe case of COVID-19 among those aged > 60 years of age. We tested varying scenarios, assuming a high cumulative infection rate of 15%, and changing assumptions regarding vaccine efficacy (including preserved and reduced effectiveness, lower even than that described in the UK (3)) and risk of severe infection (4) . The NNT, computed as 1 divided by the absolute risk reduction, was calculated for (a) fully vaccinating the unvaccinated population and (b) administering a fourth vaccine for those who had already received a third dose (assuming reaching maximal 94.5% effectiveness).

For each averted severe COVID-19 case, we estimated the numbers of people expected to develop non-local adverse reactions, based on passively reported rates published by the Israeli Ministry of Health (5).

In all scenarios, at least 1,000 recipients of third dose aged 60+ would need to receive a fourth in order to prevent one severe case of COVID-19. In all scenarios, vaccinating the unvaccinated is 5-370 times more effective in preventing a severe case compared with adding a fourth dose. Even for the lowest NNT estimation, 1,163people would need to receive a fourth dose in order to prevent one severe case.

This means that in a population with 1.3 million people aged 60+ years, 1,118 severe cases would be averted if all were vaccinated. While the reported rates of adverse events are low, these 1,118 averted cases would be associated with 30 serious adverse events. In fact, in all scenarios tested, rates of expected adverse events associated with averting a single severe case in the unvaccinated are a fraction of those foreseen in 3 rd dose recipients. It should be noted, that our last assumption of a change in vaccine effectiveness from 80% for third dose recipients to 94.5% among 4 th dose recipients is in accordance with the findings of a very recent analysis from Israeli showing a relative risk of 0.25 for a fourth vs. third dose in preventing severe disease (6) .

Notably, since the option of receiving the fourth dose became available, over 700000

Israelis have received this dose, however only 132,000 new individuals have received a first and second dose, most of them children. (7) Although the BNT162b2 vaccine is generally safe, in a scenario of limited added benefit of vaccinating the already-vaccinated, additional considerations of both harms and cost are essential. These include the costs of the vaccines themselves, the cost of mounting the vaccination campaign, and the opportunity costs of not focusing efforts on increasing the vaccination rates, even marginally, for the unvaccinated, challenging as these efforts would be. Prioritizing mass vaccination with a fourth dose would limit efforts and resources for other accepted measures to avert transmission, such as a campaign to boost the use of masks and investing in ventilation in schools.

Many questions remain regarding frequency of boosting, dosing schedules and the need for variant-specific boosters (8) . Although a third dose, administered several months following the initial vaccination, has proven its worth in "real world" settings (1) (similarly to other well-established vaccination schedules), the assumption that a fourth dose would have similar efficacy, is yet to be demonstrated. Theoretical arguments have been made for and against a continuous booster strategy, none, so far, supported by published data (9) . There is some evidence that three vaccine doses are adequate for T-cell responses and adaptation of memory B cells to the omicron variant (2, 10). However, many professional societies (e.g., ASH, ASTCT, and the CDC) in the US have recommended a fourth dose for moderate to highly immunocompromised individuals. Denmark has approved this approach for the "highly vulnerable", while other European countries have not followed suit.

Given the current level of knowledge, we question whether more is necessarily better, and whether other countries should follow Israel's lead. Other remedies quickly taken up under the cloud of COVID-19 uncertainty were eventually abandoned due to lack of efficacy and evidence of harm (10) . Given the impressive protection of the third dose against severe disease and the lower reported risk of adverse COVID-19 outcomes with the omicron variant (3, 11), it behooves the scientific community to initiate proper research, including active surveillance of adverse reactions, before making mass recommendations for a fourth dose, which may yet prove beneficial. We must direct public health efforts toward the groups at highest risk for severe disease, namely the unvaccinated, in order to preserve both public trust and public resources. *based on rates reported in the population above age 60 for the second dose (7); **based on rates reported in the population above age 60 for the third dose in vaccinated and unvaccinated people between December 21, 2021 and Jan 15, 2022 (7) 

Protection against Covid-19 by BNT162b2 Booster across Age Groups

Divergent SARS CoV-2 Omicron-specific T-and B-cell responses in COVID-19 vaccine recipients. medRxiv. 2021:2021.12.27.21268416. 3. Effectiveness of 3 doses of COVID-19 vaccines against symptomatic COVID-19 and hospitalisation in adults aged 65 years and older. Monitoring reports of the effectiveness of COVID-19 vaccination Data on the real-world efficacy of the COVID-19 vaccines: UK Health Security Agency

Hospitalisation risk for Omicron cases in England

Israeli Ministry of Health

Protection by 4th dose of BNT162b2 against Omicron in Israel

COVID-19 data dashboard: incidence of severe cases by state of vaccination: Israeli Ministry of Health

A National Strategy for COVID-19

Medical Countermeasures: Vaccines and Therapeutics

Coronavirus Briefing: Rethinking more boosters. The New York Times

Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19

Preferential expansion upon boosting of cross-reactive "pre-existing" switched memory B cells that recognize the SARS-CoV-2 Omicron variant Spike protein

Authors' contributions: all authors contributed to the conceptualization, writing and revision of this paper J o u r n a l P r e -p r o o f